Suppr超能文献

无功能性垂体腺瘤(垂体癌)的恶性转化。

Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

机构信息

Garvan Institute of Medical Research, Sydney, Australia.

Department of Endocrinology, St Vincent's Hospital, University of New South Wales, Sydney, Australia.

出版信息

Pituitary. 2018 Apr;21(2):217-229. doi: 10.1007/s11102-017-0857-z.

Abstract

Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.

摘要

无功能性垂体腺癌(NFPC)定义为具有颅脊髓或全身播散、缺乏激素分泌过多综合征的腺垂体起源肿瘤。这些是一组组织学上异质性的肿瘤,包括促性腺激素、无细胞、促皮质激素、生长激素或催乳素细胞谱系的“沉默”肿瘤以及多激素 Pit-1 肿瘤。NFPC 极为罕见,因此描述的病例很少。本综述在文献中确定了 38 例 NFPC 患者。大多数患者观察到复发性侵袭性无功能性垂体腺瘤(NFPA)。已经确定了一些因素作为侵袭性行为潜在标志物,包括肿瘤快速生长、放疗后生长、激素分泌的增加或转变以及增殖标志物升高。通常情况下,从最初的 NFPA 出现到转移的发现有几年的潜伏期,只有 5 例报告在出现后 1 个月内出现快速进展的恶性疾病。治疗选择包括肿瘤切除术、放疗和替莫唑胺化疗,推荐替莫唑胺作为一线全身治疗。尽管有长期存活的病例描述,但预后通常非常差(中位生存 8 个月)。肿瘤分子谱分析的改进可能有助于预测肿瘤行为、指导治疗选择和确定新的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验